Talis Enterprise Value Over E B I T D A from 2010 to 2024

TLIS Stock  USD 9.16  0.21  2.35%   
Talis Biomedical Enterprise Value Over EBITDA yearly trend continues to be comparatively stable with very little volatility. Enterprise Value Over EBITDA is likely to outpace its year average in 2024. From the period from 2010 to 2024, Talis Biomedical Enterprise Value Over EBITDA quarterly data regression had r-value of  0.86 and coefficient of variation of (104.76). View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
0.71706312
Current Value
0.75
Quarterly Volatility
1.58525407
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Talis Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Talis main balance sheet or income statement drivers, such as Net Interest Income of 50.4 K, Interest Income of 50.4 K or Depreciation And Amortization of 3.2 M, as well as many exotic indicators such as Price To Sales Ratio of 34.51, Dividend Yield of 0.0 or PTB Ratio of 0.21. Talis financial statements analysis is a perfect complement when working with Talis Biomedical Valuation or Volatility modules.
  
This module can also supplement various Talis Biomedical Technical models . Check out the analysis of Talis Biomedical Correlation against competitors.

Latest Talis Biomedical's Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of Talis Biomedical Corp over the last few years. It is Talis Biomedical's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Talis Biomedical's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Slightly volatile
   Enterprise Value Over E B I T D A   
       Timeline  

Talis Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean(1.51)
Geometric Mean1.53
Coefficient Of Variation(104.76)
Mean Deviation1.42
Median(2.69)
Standard Deviation1.59
Sample Variance2.51
Range3.4363
R-Value0.86
Mean Square Error0.68
R-Squared0.75
Significance0.000032
Slope0.31
Total Sum of Squares35.18

Talis Enterprise Value Over E B I T D A History

2024 0.75
2023 0.72
2022 0.74
2021 0.67
2020 0.19
2019 -1.58

About Talis Biomedical Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Talis Biomedical income statement, its balance sheet, and the statement of cash flows. Talis Biomedical investors use historical funamental indicators, such as Talis Biomedical's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Talis Biomedical investors may use each financial statement separately, they are all related. The changes in Talis Biomedical's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Talis Biomedical's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Talis Biomedical Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Talis Biomedical. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA 0.72  0.75 

Currently Active Assets on Macroaxis

When determining whether Talis Biomedical Corp is a strong investment it is important to analyze Talis Biomedical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Talis Biomedical's future performance. For an informed investment choice regarding Talis Stock, refer to the following important reports:
Check out the analysis of Talis Biomedical Correlation against competitors.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Talis Stock analysis

When running Talis Biomedical's price analysis, check to measure Talis Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Talis Biomedical is operating at the current time. Most of Talis Biomedical's value examination focuses on studying past and present price action to predict the probability of Talis Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Talis Biomedical's price. Additionally, you may evaluate how the addition of Talis Biomedical to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Is Talis Biomedical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Talis Biomedical. If investors know Talis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Talis Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(31.43)
Revenue Per Share
0.543
Quarterly Revenue Growth
(0.94)
Return On Assets
(0.34)
Return On Equity
(0.69)
The market value of Talis Biomedical Corp is measured differently than its book value, which is the value of Talis that is recorded on the company's balance sheet. Investors also form their own opinion of Talis Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Talis Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Talis Biomedical's market value can be influenced by many factors that don't directly affect Talis Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Talis Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Talis Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Talis Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.